Antibody against fibroblast growth factor-23

Details Antibody against fibroblast growth factor-23 Antibody against fibroblast growth factor-23

2011-04-12

2011-04-12

Skelding, Zachary (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388240

Reexamination Certificate

active

07923012

ABSTRACT:
The purpose of the present invention is to provide an antibody against fibroblast growth factor 23. The antibody is obtained by immunizing an animal with a polypeptide which comprises an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 by deletion, substitution, or addition of 1 or several amino acids, and has fibroblast growth factor-23 activity and activity to control phosphate metabolism or vitamin D metabolism, and is shown by the following (a), (b), or (c):(a) an antibody, which recognizes an amino acid sequence between the 180thand the 194th, or the 237thand the 251stamino acid residues represented by SEQ ID NO: 1;(b) an antibody, which is produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268; or(c) an antibody, which is competitive with the antibody produced by the hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268 upon binding with the polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1.

REFERENCES:
patent: 5585089 (1996-12-01), Queen et al.
patent: 5958879 (1999-09-01), Kopchick et al.
patent: 6001358 (1999-12-01), Black et al.
patent: 6617118 (2003-09-01), Roffler et al.
patent: 7094551 (2006-08-01), Zahradnik et al.
patent: 7223563 (2007-05-01), Econs et al.
patent: 7314618 (2008-01-01), Econs et al.
patent: 2002/0156001 (2002-10-01), Econs et al.
patent: 2004/0082506 (2004-04-01), Yamashita et al.
patent: 2004/0171825 (2004-09-01), Bougueleret et al.
patent: 2006/0160181 (2006-07-01), Luethy et al.
patent: 2009/0110677 (2009-04-01), Yamashita et al.
patent: 2009/0148461 (2009-06-01), Yamazaki et al.
patent: 2418215 (2002-01-01), None
patent: 1446227 (2003-10-01), None
patent: 120694 (1984-10-01), None
patent: 125023 (1984-11-01), None
patent: 0314161 (1988-10-01), None
patent: 1466925 (2004-10-01), None
patent: 2188638 (1987-10-01), None
patent: S-61-178926 (1986-11-01), None
patent: H-02-117920 (1990-02-01), None
patent: WO 99/60017 (1999-11-01), None
patent: WO 00/10383 (2000-03-01), None
patent: WO 00/60085 (2000-10-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 01/66595 (2001-03-01), None
patent: WO 01/66596 (2001-03-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/42451 (2001-06-01), None
patent: WO 0149740 (2001-07-01), None
patent: WO 01/60850 (2001-08-01), None
patent: WO 01/61007 (2001-08-01), None
patent: WO 02/08271 (2002-01-01), None
patent: WO 02/14504 (2002-02-01), None
patent: WO 02/76467 (2002-03-01), None
patent: WO 02/088358 (2002-11-01), None
patent: WO 02/043478 (2004-05-01), None
patent: WO 2006/078072 (2006-07-01), None
patent: WO 2008/092019 (2008-07-01), None
Campbell, A.M., Monoclonal antibody technology, Elsevier Science Publishers, Inc., 1984, pp. 1-32.
Wen et al., Proc. Natl. Acad. Sci. USA 98 (8): 4622-27 (2001).
Superti-Furga, et al., American Journal of Medical Genetics (Semin. Med. Genet.) 106: 282-93 (2001).
Lorenz-Depiereux et al., Eur. J. Human Genetics 9 (Supplement 1) pp. P0772 (2001).
Yu et al., Endocrinology. Nov. 2005;146(11):4647-56.
Bost et al., Immunol. Invest. 1988; 17:577-586.
Mohammadi et al., Cytokine Growth Factor Rev. Apr. 2005;16(2):107-37.
International Search Report.
Takashi Shimada et al., “Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia”, Proc. Natl. Acad. Sci., USA, May 22, 2001, vol. 98, Issue 11, pp. 6500-6505.
Yuji Yamazaki et al., “Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia”, The Journal of Clinical Endocrinology & Metabolism, (Nov. 2002), vol. 87, No. 11, pp. 4957-4966.
Yuji Yamazaki et al, “Detection of Circulating FGF-23 by Monoclonal Antibodies Against Recombinant Human FGF-23”, Journal of the American Society of Nephrology, (Sep. 2002), vol. 13, (Program and Abstract Issue), p. 499A.
Takashi Shimada et al, “FGF-23 Is a Novel Humoral Factor Regulating Vitamin D Metabolism”, Journal of the American Society of Nephrology, (Sep. 2002), vol. 13, (Program & Abstract Issue), p. 28A.
Takashi Shimada et al., “Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo”, Endocrinology, (Aug. 2002), vol. 143, No. 8 pp. 3179-3182.
Yuji Yamazaki et al, “Development of the ELISA System Using Monoclonal Antibodies against FGF-23 and Demonstration of Increased Plasma Concentration of FGF-23 in Tumor-Induced Osteomalacia”, ENDO, 2002, The Endocrine Society's 84thAnnual Meeting, Program & Abstract, p. 66.
Y. Yamazaki et al., “FGF-23 Protein is Present in Normal Plasma and Is increased in Patients with Tumor-Induced Osteomalacia”, (Sep. 2002), The Journal of Bone and Mineral Research, vol. 17, suppl. 1, p. 159.
Kenneth E. White et al., “Autosomal-dominant hypophosphatemic rickets (ADHR) mutation stabilize FGF-23”, Kidney International, vol. 60 (2001), pp. 2079-2086.
Non-Final Office Action for U.S. Appl. No. 10/344,339 dated Jan. 18, 2008.
Advisory Action for U.S. Appl. No. 10/344,339 dated Dec. 7, 2007.
Final Office Action for U.S. Appl. No. 10/344,339 dated Jun. 22, 2007.
Non-Final Office Action for U.S. Appl. No. 10/344,339 dated Sep. 27, 2006.
Notice of Allowance for Korean Patent Application No. 10-2003-7001931 dated Nov. 26, 2008—international, counterpart to U.S. Appl. No. 10/344,339.
Office Action for Canadian Patent Application No. 2,418,802 dated Feb. 13, 2009—international, counterpart to U.S. Appl. No. 10/344,339.
Supplementary European Search Report of European Patent Application No. EP 01 95 8379 dated May 27, 2005—international, counterpart to U.S. Appl. No. 10/344,339.
International Search Report of PCT Patent Application No. PCT/JP2008/052918 dated Mar. 13, 2008—international, counterpart to U.S. Appl. No. 12/030,593.
Aono et al., “The improving effect of anti FGF23 neutralizing antibody on hypophosphatemia and rickets of Hyp mice”,The Japanese Society for Bone and Mineral Research(JSBMR), Annual Meeting of the JSBMR, 22ndProgram, Aug. 2004, vol. 22, pp. 137.
Ando, et al.,Tan-Clone-Kotai-Jikken-Manual(“Experimental Manual for Monoclonal Antibody”) (written by and published by Kodansha Scientific, Ltd., Tokyo, Japan (1991).
Antibody Engineering, A Practical Approach, IRL Press, 1996.
Antibody Engineering, A Practical Guide, W.H. Freeman and Company, 1992.
Aschinberg et al., “Vitamin D-resistant rickets associated with epidermal nevus syndrome: Demonstration of a phosphaturic substance in the dermal lesions,”The Journal of Pediatrics,vol. 91, No. 1, Jul. 1997, pp. 56-60, The C.V. Mosby Company, St. Louis, Mo.
Baker and Worthley, “The Essentials of Calcium, Magnesium and Phosphate Metabolism: Part II. Disorders,”Critical Care & Resuscitation.,2000, vol. 4, pp. 307-315.
Better et al., “Escherichia coliSecretion of an Active Chimeric Antibody Fragment,”Science,May 20, 1998 (nti), vol. 240, pp. 1041-1043.
Benjannet et al., “αl -Antitrypsin Portland Inhibits Processing of Precursors Mediated by Proprotein Convertases Primarily within the constitutive Secretory Pathway,”The Journal of Biological Chemistry,vol. 272, No. 42, Oct. 17, 1997, pp. 2610-2618, The American Society for Biochemistry and Molecular Biology, Inc.
Briand et al., “Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies”,Journal of Immunnological Methods,vol. 156, No. 2, 1992, pp. 255-265, Elsevier Science Publishers B.V.
Bruggemann, et al., “The Immunogenicity of Chimeric Antibodies”,J. Exp. Med.,Dec. 1989, vol. 170, No. 6, pp. 2153-2157.
Cai et al., “Brief Report: Inhibition of Renal Phosphate Transport by a Tumor Product in a Pa

Affiliated with

Also associated with

Rating

Antibody against fibroblast growth factor-23 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody against fibroblast growth factor-23, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody against fibroblast growth factor-23 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2687016